

IN THE CLAIMS

Please amend the claims as follows. This listing of claims replaces all prior versions.

1-17. (Canceled).

18. (Currently amended) A method of amplifying a segment of a VKOR genomic nucleotide sequence, ~~wherein said segment is in a noncoding region of the nucleotide sequence,~~ comprising:

a) choosing a first oligonucleotide primer from the 3' end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

b) choosing a second oligonucleotide primer from the 5' end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

c) adding said first primer and said second primer to a nucleic acid sample; and

d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein said nucleic acid sample is from a subject in need of warfarin therapy~~segment is in a noncoding region of the nucleotide sequence.~~

19. (Previously presented) The method of claim 18, wherein the amplified segment of step (d) is less than 100 base pairs in length.

20. (Previously presented) The method of claim 18, wherein the amplified segment of step (d) comprises a single nucleotide polymorphism.

21-22. (Canceled).

23. (Previously presented) The method of claim 18, wherein the first oligonucleotide primer is at least 15 nucleotides in length.

24. (Previously presented) The method of claim 18, wherein the second oligonucleotide primer is at least 15 nucleotides in length.

25. (Currently amended) A method of amplifying a segment of a VKOR genomic nucleotide sequence, ~~wherein said segment is in a noncoding region of the nucleotide sequence,~~ comprising:

a) choosing a first oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

b) choosing a second oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8 that differs in nucleotide sequence from the first oligonucleotide primer;

c) adding said first primer and said second primer to a nucleic acid sample; and

d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein said nucleic acid sample is from a subject in need of warfarin therapy~~segment is in a noncoding region of the nucleotide sequence.~~

26. (Previously presented) The method of claim 25, wherein the amplified segment of step (d) is less than 100 base pairs in length.

27. (Previously presented) The method of claim 25, wherein the amplified segment of step (d) comprises a single nucleotide polymorphism.

28-29. (Canceled).

30. (Previously presented) The method of claim 25, wherein the first oligonucleotide primer is at least 15 nucleotides in length.

31. (Previously presented) The method of claim 25, wherein the second oligonucleotide primer is at least 15 nucleotides in length.

32-45. (Canceled).